The addition of ivosidenib (Tibsovo) to azacitidine led to a threefold survival improvement for newly diagnosed IDH1-mutant acute myeloid leukemia (AML) patients who were ineligible for intensive ...
New data details molecular characterization of clinical response in patients with IDH1-mutated, newly-diagnosed acute myeloid leukemia (AML) treated with TIBSOVO® (ivosidenib tablets) in combination ...
New data details molecular characterization of clinical response in patients with IDH1-mutated, newly-diagnosed acute myeloid leukemia (AML) treated with TIBSOVO ® (ivosidenib tablets) in combination ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results